Select Publications
Book Chapters
2019, 'HIV Infection as a Model of Accelerated Immunosenescence', in Handbook of Immunosenescence, Springer International Publishing, pp. 1961 - 1989, http://dx.doi.org/10.1007/978-3-319-99375-1_50
,2018, 'Mechanisms for Controlling HIV-1 infection: a Gene Therapy Approach', in In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders, http://dx.doi.org/10.5772/intechopen.72962
,2017, 'HIV Infection as a Model of Accelerated Immunosenescence.', in Bachtarzi H (ed.), Handbook of Immunosenescence Basic Understanding and Clinical Implications, http://dx.doi.org/10.1007/978-3-319-64597-1_50-1
,2014, 'AIDS : Clinical Manifestations', in Encyclopaedia of Life Sciences, John Wiley & Sons, http://dx.doi.org/10.1002/9780470015902.a0002237.pub3
,2013, 'The Immunocompromised Patient', in Fulde G; Fulde S (ed.), Emergency Medicine: the Principles of Practice, Churchill Livingston, Sydney, pp. 862 - 889, https://www.elsevier.com/books/emergency-medicine/fulde/978-0-7295-8146-2
,2012, 'Chapter 6 Acute HIV infection', in Sande's HIV/AIDS Medicine, Elsevier, pp. 77 - 88, http://dx.doi.org/10.1016/b978-1-4557-0695-2.00006-7
,2009, 'Immune Restoration Diseases', in Hoy J; Lewin S; Post JJ; Street A (ed.), HIV Management in Australasia: a guide for clinical care, pp. 287 - 294
,2009, 'The immunosuppressed patient', in Fulde G (ed.), Emergency Medicine, the Principles of Practice, Elsevier, Australia, pp. 665 - 686, http://shop.mja.com.au/
,2009, 'The immunosuppressed patient', in Emergency Medicine, Elsevier, pp. 665 - 686, http://dx.doi.org/10.1016/b978-0-7295-3876-3.10042-5
,2008, 'Acute HIV Infection', in Volberding PA; Sande MA; Greene WC; Lange JMA (ed.), Global HIV/AIDS Medicine, Elsevier Inc, Philadelphia, PA, pp. 63 - 74
,2008, 'CHAPTER 6 Acute HIV Infection', in Global HIV/AIDS Medicine, Elsevier, pp. 63 - 74, http://dx.doi.org/10.1016/b978-1-4160-2882-6.50010-1
,2008, 'Infeccion primaria por HIV. [Primary HIV-1 Infection]', in Benettuci JA (ed.), SIDA y Enfermedades Associadas (AIDS and Infectious Diseases), 3a edicion., FUNDAI, Buenos Aires, pp. 155 - 170
,2007, 'Acute HIV Infection', in Global HIV/AIDS Medicine, pp. 63 - 74, http://dx.doi.org/10.1016/B978-1-4160-2882-6.50010-1
,2005, 'Therapeutic vaccination in PHI', in Jenssen H; Jager H (ed.), Primary HIV Infection ? Pathology, Diagnosis, Management, Thieme, Stuttgart, pp. 48 - 63
,1997, 'Early HIV-induced immune depletion', in Stewart GJ (ed.), Managing HIV, Medical Journal of Australia
,1997, 'Strategies in managing HIV', in Stewart GJ (ed.), Managing HIV
,Journal articles
2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-47720-8
,2024, 'Condom Failure Among HIV-Negative Men in Serodiscordant Relationships in Australia, Brazil, and Thailand', AIDS and Behavior, 28, pp. 3587 - 3595, http://dx.doi.org/10.1007/s10461-024-04431-x
,2024, 'Next-Generation Sequencing Methods for Near-Real-Time Molecular Epidemiology of HIV and HCV', Reviews in Medical Virology, 34, http://dx.doi.org/10.1002/rmv.70001
,2024, 'Current State of Therapeutics for HTLV-1', Viruses, 16, http://dx.doi.org/10.3390/v16101616
,2024, 'Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial', The Lancet HIV, 11, pp. e436 - e448, http://dx.doi.org/10.1016/S2352-3018(24)00089-4
,2024, 'Low HIV drug resistance prevalence among recently diagnosed HIV-positive men who have sex with men in a setting of high PrEP use', Journal of the International AIDS Society, 27, http://dx.doi.org/10.1002/jia2.26308
,2024, 'Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study', The Lancet Microbe, 5, pp. e559 - e569, http://dx.doi.org/10.1016/S2666-5247(24)00015-6
,2024, 'Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial', Journal of Virus Eradication, 10, http://dx.doi.org/10.1016/j.jve.2024.100381
,2024, 'Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials', Journal of Infectious Diseases, 229, pp. 1229 - 1238, http://dx.doi.org/10.1093/infdis/jiad425
,2024, 'Advances in HIV Gene Therapy', International Journal of Molecular Sciences, 25, http://dx.doi.org/10.3390/ijms25052771
,2024, 'Molecular epidemiology to aid virtual elimination of HIV transmission in Australia', Virus Research, 341, http://dx.doi.org/10.1016/j.virusres.2024.199310
,2024, 'Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis', Frontiers in Neurology, 15, http://dx.doi.org/10.3389/fneur.2024.1350848
,2024, 'Perplexing case of abdominal pain with eosinophilia and fasciitis', Gut, http://dx.doi.org/10.1136/gutjnl-2024-332580
,2024, 'David Albert Cooper 1949–2018', Historical Records of Australian Science, http://dx.doi.org/10.1071/hr23032
,2024, 'Novel clinical applications of functional assays to measure antigen-specific cellular immunity', Pathology, 56, pp. S27 - S27, http://dx.doi.org/10.1016/j.pathol.2023.12.101
,2023, 'Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients', Nature Communications, 14, http://dx.doi.org/10.1038/s41467-023-36295-5
,2023, 'Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0289907
,2023, 'Delabeling, safety, and impact of β-lactam allergy testing: A systematic review', Journal of Allergy and Clinical Immunology: Global, 2, http://dx.doi.org/10.1016/j.jacig.2023.100160
,2023, 'Agreements, Behaviour, and Change: Sex Outside the Relationship in Male HIV-negative Partners in HIV Serodiscordant Relationships in Australia, Brazil, and Thailand', AIDS and Behavior, 27, pp. 3098 - 3108, http://dx.doi.org/10.1007/s10461-023-04030-2
,2023, 'Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial', The Lancet Respiratory Medicine, 11, pp. 791 - 803, http://dx.doi.org/10.1016/S2213-2600(23)00147-9
,2023, 'Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2', Antiviral Research, 217, http://dx.doi.org/10.1016/j.antiviral.2023.105677
,2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352, http://dx.doi.org/10.1002/acn3.51825
,2023, 'Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial', The Lancet Infectious Diseases, 23, pp. 847 - 855, http://dx.doi.org/10.1016/S1473-3099(23)00067-1
,2023, 'T follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults', Immunology and Cell Biology, 101, pp. 504 - 513, http://dx.doi.org/10.1111/imcb.12635
,2023, 'The crossroads: divergent roles of virus-specific CD4+ T lymphocytes in determining the outcome for human papillomavirus infection', Immunology and Cell Biology, 101, pp. 525 - 534, http://dx.doi.org/10.1111/imcb.12650
,2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, http://dx.doi.org/10.1016/j.ebiom.2023.104545
,2023, 'Viral competition assay to assess the role of HIV-1 proteins in immune evasion', STAR Protocols, 4, http://dx.doi.org/10.1016/j.xpro.2022.102025
,2023, 'Parallel analysis of multiple human memory CD4+ T-cell subsets within antigen-specific responses using cell proliferation dyes', Immunology and Cell Biology, 101, pp. 171 - 178, http://dx.doi.org/10.1111/imcb.12606
,2023, 'Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses', American Journal of Hematology, 98, pp. 131 - 139, http://dx.doi.org/10.1002/ajh.26619
,2023, 'Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19', Clinical Immunology, 246, http://dx.doi.org/10.1016/j.clim.2022.109209
,2023, 'Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy', eJHaem, 4, pp. 728 - 732, http://dx.doi.org/10.1002/jha2.724
,2023, 'Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.', NEJM Evid, 2, http://dx.doi.org/10.1056/evidoa2200302
,2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1032911
,2022, 'Phenotypic and functional characteristics of highly differentiated CD57+NKG2C+NK cells in HIV-1-infected individuals', Clinical and Experimental Immunology, 210, pp. 163 - 174, http://dx.doi.org/10.1093/cei/uxac082
,